NCT02784756View on ClinicalTrials.gov

Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

NACompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 29, 2020

Study Completion Date

April 30, 2020

Conditions
Cytomegalovirus Viraemia
Interventions
DEVICE

Quantiferon-CMV assay

Trial Locations (6)

28041

Hospital Universitario 12 de Octubre, Madrid

T6G 2G3

University of Alberta Hospital, Edmonton

V6Z 1Y6

St. Paul's Hospital - Providence Health, Vancouver

N6A 4V2

London Health Sciences Centre, London

M5C 2T2

St. Michael's Hospital, Toronto

M5G 2N2

University Health Network, Toronto General Hospital, Toronto

All Listed Sponsors
collaborator

Canadian National Transplant Research Program

OTHER

lead

University Health Network, Toronto

OTHER

NCT02784756 - Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients | Biotech Hunter | Biotech Hunter